BOT

2.63%

37.0¢ botanix pharmaceuticals ltd

Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-404

First 404 Last

Share
Profile

Follow
Hingdog

23,539 Posts.

1482

24/10/19

01:31

Post #: 41041727
Share

Originally posted by Southoz ↑

Not exactly. As a first step have a read through the FDA guidance for acne trials to understand the issues.

https://www.fda.gov/media/71152/download

The key design issue is that methodologically from the analysis of absolute lesion number change or percent lesion change clinical significance just doesn’t magically pop out.

So the FDA turns the question upside down.

Success or failure is defined by IGA change (2 points) which represents clinically significant improvement. With the quantitative lesion count providing the magnitude of change.

But clinical significance is the first key … because the FDA believe drugs shouldn’t be approved just because they help things … but rather that help needs to be clinically significant.

There is a big long complicated history to why the FDA thinks the way they do about this. .

But in brief the IGA operates like the Clinical Global Impressions (CGI) scale that is commonly used in neuroscience.

Here for example you might improve 3 points on a memory test. But what that means in the real world is highly unclear.

So the FDA promotes the CGI scale as a co-primary to the memory test .… where it wants a clinician to actually qualitatively make a judgment that this change in memory score has made a real world difference …the person can get to the shops and home again now where as before they couldn’t and this has led to a major improvement in quality of life.

All very complicated.

Keeping it simple … would you sign up to a treatment that produces clinical significant improvement in less than 10% of people.

If you had a daughter with Retts disease quite possibly … because there are no other treatments and we are talking about life and death. But not for acne treatment where there are more effective options; defined as higher percentages of people showing two or more point improvement on the IGA.

But that’s it for me for a while … back to trying make difference in the real world myself.

Expand

Here is the IGA success for the recently FDA approved Foamix FMX101. The results look to me(a mug punter) be in line with BTX1503 Australian results?

BOT Price at posting: 12.5¢ Sentiment: None Disclosure: Held
11 Upvote

4 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 247 more messages in this thread...

First 404 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 37.0¢		Change -0.010(2.63%)		Mkt cap ! $671.1M

Open	High	Low	Value	Volume
38.0¢	38.0¢	37.0¢	$1.949M	5.207M

Buyers (Bids)

No.	Vol.	Price($)
7	163455	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
37.5¢	33207	2

View Market Depth

No.	Vol.	Price($)
4	130837	0.370
10	99517	0.365
16	271384	0.360
7	220353	0.355
26	1051912	0.350

Price($)	Vol.	No.
0.380	44778	1
0.385	245000	3
0.390	10960	1
0.395	123443	3
0.400	179748	4

Last trade - 16.10pm 04/10/2024 (20 minute delay)

BOT (ASX) Chart

Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-404

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-404

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News